Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study.

The purpose of this retrospective cohort study was to examine the associations among chronic kidney disease, anemia, and risk of death among patients with heart failure. Retrospective cohort study. Patients with a principal diagnosis of heart failure (ICD9 codes 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, and 428.xx) were included. Chronic kidney disease (CKD) was defined as a serum creatinine >1.4 mg/dl for women and >1.5 mg/dl for men. There were 665 eligible patients in the sample with a mean (SD) age of 75.7 (10.9) yr; 60% were women, 71% were white, and 38% had CKD. On admission, a hematocrit > or =40% was found for 30.3% of the patients; 22.9% had a hematocrit between 36% and 40%, 33.2% between 30% and 35%, and 13.6% had a hematocrit of <30%. The 1-yr death rates among individuals with and without CKD were 44.9% and 31.4%, respectively (relative risk [RR], 1.43; 95% confidence interval [CI], 1.17 to 1.75). The mortality at 1 yr was 31.2% for individuals with a hematocrit > or =40%; 33.8% (RR, 1.08; 95% CI. 0.79 to 1.47) for hematocrit 36 to 39%; 36.7% (RR, 1.17; 95% CI, 0.89 to 1.54) for hematocrit between 30 and 35%; and 50.0% (RR, 1.60; 95% CI, 1.19 to 2.16) for those with a hematocrit <30% (chi(2) for trend was 7.37; P = 0.007). Both hematocrit and serum creatinine were independently associated with increased risk of death during follow-up after controlling for other patient risk factors. In conclusion, CKD and anemia are frequent among older patients with heart failure and are independent predictors of subsequent risk of death.

[1]  A. Collins,et al.  Trends in anemia at initiation of dialysis in the United States. , 2001, Kidney international.

[2]  W. Rand,et al.  Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[3]  J. Yee,et al.  Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  I. Shapira,et al.  The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. , 2001, Journal of the American College of Cardiology.

[5]  G. V. van Montfrans,et al.  Circadian rhythms in systemic hemodynamics and renal function in healthy subjects and patients with nephrotic syndrome. , 2001, Kidney international.

[6]  D. Bates,et al.  Relationship between hematocrit and renal function in men and women. , 2001, Kidney international.

[7]  J. Adamson,et al.  IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  David Roth,et al.  A simplified equation to predict glomerular filtration rate from serum creatinine , 2000 .

[9]  I. Shapira,et al.  The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. , 2000, Journal of the American College of Cardiology.

[10]  S G Thompson,et al.  Survival of patients with a new diagnosis of heart failure: a population based study , 2000, Heart.

[11]  M. Hori,et al.  Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  L. Stevenson,et al.  Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. , 1999, American heart journal.

[13]  J. Singer,et al.  Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  P. Armstrong,et al.  Insights into the contemporary epidemiology and outpatient management of congestive heart failure. , 1999, American heart journal.

[15]  J. Hosenpud Levosimendan, a novel myofilament calcium sensitizer, allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure , 1999 .

[16]  Thomas D. Giles,et al.  Consensus recommendations for the management of chronic heart failure: Introduction , 1999 .

[17]  M. Komajda,et al.  Risk stratification in chronic heart failure. , 1998, European heart journal.

[18]  A. Barrientos,et al.  Cardiovascular effects of recombinant human erythropoietin in predialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  F. Fabbian,et al.  Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. , 1997 .

[20]  A. Besarab,et al.  Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. , 1997, Kidney international.

[21]  M. Rich,et al.  Course and prognosis in patients > or = 70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. , 1997, The American journal of cardiology.

[22]  J. Vítovec,et al.  Non-invasive prognostic factors in chronic heart failure. One-year survival of 300 patients with a diagnosis of chronic heart failure due to ischemic heart disease or dilated cardiomyopathy. , 1996, International journal of cardiology.

[23]  A. O. Obasohan,et al.  Heart failure in Nigerian hypertensive patients: the role of renal dysfunction. , 1995, International journal of cardiology.

[24]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[25]  J. Hansen,et al.  Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. , 1994, European heart journal.

[26]  P. Deedwania,et al.  Predictors of mortality in patients with heart failure. , 1994, Cardiology clinics.

[27]  R. Wolfe,et al.  An estimate of the size of the US predialysis population with renal insufficiency and anemia. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  J Keegan,et al.  Predictors of prognosis in severe chronic heart failure. , 1992, American heart journal.

[29]  A. Nissenson,et al.  Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects. , 1991, Annals of internal medicine.

[30]  S. Gottlieb,et al.  The erythrocyte sedimentation rate in congestive heart failure. , 1991, The New England journal of medicine.

[31]  Franciosa Ja Why patients with heart failure die: hemodynamic and functional determinants of survival. , 1987 .

[32]  M. Packer,et al.  Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. , 1986, Circulation.

[33]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[34]  R. Adolph,et al.  Cardiovascular effects of anemia. , 1972, American heart journal.

[35]  W. Abelmann,et al.  The Hemodynamic Response to Chronic Anemia , 1969, Circulation.